BR112023014826A2 - Agentes de ligação de hhla2 com nova atividade - Google Patents
Agentes de ligação de hhla2 com nova atividadeInfo
- Publication number
- BR112023014826A2 BR112023014826A2 BR112023014826A BR112023014826A BR112023014826A2 BR 112023014826 A2 BR112023014826 A2 BR 112023014826A2 BR 112023014826 A BR112023014826 A BR 112023014826A BR 112023014826 A BR112023014826 A BR 112023014826A BR 112023014826 A2 BR112023014826 A2 BR 112023014826A2
- Authority
- BR
- Brazil
- Prior art keywords
- hhla2
- binding agents
- new activity
- activity
- new
- Prior art date
Links
- 239000011230 binding agent Substances 0.000 title abstract 3
- 102100035943 HERV-H LTR-associating protein 2 Human genes 0.000 title 1
- 101001021491 Homo sapiens HERV-H LTR-associating protein 2 Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Catalysts (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
agentes de ligação de hhla2 com nova atividade. a presente invenção refere-se a agentes de ligação de hhla2 com nova atividade e usos dos mesmos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163142832P | 2021-01-28 | 2021-01-28 | |
| PCT/US2022/014423 WO2022165258A1 (en) | 2021-01-28 | 2022-01-28 | Hhla2 binding agents with novel activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023014826A2 true BR112023014826A2 (pt) | 2023-10-03 |
Family
ID=82652818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023014826A BR112023014826A2 (pt) | 2021-01-28 | 2022-01-28 | Agentes de ligação de hhla2 com nova atividade |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4284431A1 (pt) |
| JP (1) | JP2024509501A (pt) |
| KR (1) | KR20230135637A (pt) |
| CN (1) | CN116981476A (pt) |
| AU (1) | AU2022214939A1 (pt) |
| BR (1) | BR112023014826A2 (pt) |
| CA (1) | CA3207494A1 (pt) |
| IL (1) | IL304584A (pt) |
| MX (1) | MX2023008182A (pt) |
| WO (1) | WO2022165258A1 (pt) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015167948A1 (en) * | 2014-04-30 | 2015-11-05 | Albert Einstein College Of Medicine Of Yeshiva University | Tmigd2 and its derivatives as blockers or binders of cancer-expressed hhla2 for immunotherapies |
| JP7438098B2 (ja) * | 2017-07-06 | 2024-02-26 | メルス ナムローゼ フェンノートシャップ | 細胞により発現される生物学的活性を調節する結合分子 |
| EP3773658A4 (en) * | 2018-04-06 | 2022-04-27 | Dana-Farber Cancer Institute, Inc. | KIR3DL3 USEFUL AS HHLA2 RECEPTOR, ANTI-HHLA2 ANTIBODIES AND THEIR USES |
-
2022
- 2022-01-28 AU AU2022214939A patent/AU2022214939A1/en active Pending
- 2022-01-28 CN CN202280012137.1A patent/CN116981476A/zh active Pending
- 2022-01-28 BR BR112023014826A patent/BR112023014826A2/pt unknown
- 2022-01-28 KR KR1020237028708A patent/KR20230135637A/ko unknown
- 2022-01-28 WO PCT/US2022/014423 patent/WO2022165258A1/en active Application Filing
- 2022-01-28 CA CA3207494A patent/CA3207494A1/en active Pending
- 2022-01-28 MX MX2023008182A patent/MX2023008182A/es unknown
- 2022-01-28 EP EP22746752.9A patent/EP4284431A1/en active Pending
- 2022-01-28 JP JP2023544261A patent/JP2024509501A/ja active Pending
-
2023
- 2023-07-19 IL IL304584A patent/IL304584A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL304584A (en) | 2023-09-01 |
| WO2022165258A1 (en) | 2022-08-04 |
| AU2022214939A1 (en) | 2023-07-20 |
| CA3207494A1 (en) | 2022-08-04 |
| JP2024509501A (ja) | 2024-03-04 |
| KR20230135637A (ko) | 2023-09-25 |
| CN116981476A (zh) | 2023-10-31 |
| EP4284431A1 (en) | 2023-12-06 |
| MX2023008182A (es) | 2023-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021024108A2 (pt) | Inibidores de tead e usos dos mesmos | |
| BR112019021277A8 (pt) | Curativos extensíveis | |
| BRPI0513916A (pt) | moduladores de pirrol-piridina cinase | |
| BR112015023557A2 (pt) | proteínas de ligações dual específicas direcionadas contra tnfa | |
| EA201001628A1 (ru) | Модифицированные полипептиды фактора vii и их применение | |
| BRPI0708353A8 (pt) | Compostos terapêuticos | |
| BR112022003527A2 (pt) | Cianopirrolidinas substituídas com atividade como inibidores de usp30 | |
| CL2020003202A1 (es) | Piridinil y pirazinil-(aza)indolsulfonamidas | |
| BR112021025421A2 (pt) | Moléculas de anticorpo humanizado para cd138 e os usos dos mesmos | |
| EP2596122A4 (en) | MODULATORS OF SIRT5 AND TESTS FOR SCREENING | |
| EA201390704A1 (ru) | Соединения, ингибирующие металлоферменты | |
| BR112021008012A2 (pt) | Conjugados de anticorpo de cisteína engenheirada-fármaco com ligantes contendo peptídeo | |
| BR112022017192A2 (pt) | Variantes de transglutaminase | |
| BR112019021325A8 (pt) | Curativos extensíveis | |
| BR112019005783A2 (pt) | agentes de ligação monoclonal com cmet, conjugados de fármaco dos mesmos e usos dos mesmos | |
| CO2022005587A2 (es) | Moléculas de fusión del ecd de siglec-9 y métodos de uso de estas | |
| BR112016006321A2 (pt) | enzima engenheirada tendo atividade aceto acetil-coa hidrolase, micro-organismos compreendendo a mesma, e processos de uso da mesma | |
| BR112023014826A2 (pt) | Agentes de ligação de hhla2 com nova atividade | |
| BR112022011147A2 (pt) | Compostos para inibir fatores de neovascularização e uso dos mesmos | |
| BR112022007944A2 (pt) | Anticorpos trem2 e usos dos mesmos | |
| BR112023015050A2 (pt) | Anticorpos anti-met e usos dos mesmos | |
| BR112022000005A2 (pt) | Agentes de ligação a cd38 e usos dos mesmos | |
| CR20200063A (es) | Uso terapéutico o no terapéutico de protozoos del género willaertia como fungistático y/o fungicida | |
| BR112021019337A2 (pt) | Anticorpo anti-fgf23 | |
| BR112022008287A2 (pt) | Métodos de tratamento usando um modulador de mtorc1 |